Table 2.

Univariate and multivariate analyses of the factors associated with PFS following ICI treatment

	Univariate analysis		Multivariate analysis
	HR (95% CI)	p	HR (95% CI)	p
Sex female vs. male (n = 27 vs. 31)	1.55 (0.89–2.67)	0.12	0.67 (0.25–1.75)	0.41
Age > 70 vs. ≤ 70 (n = 25 vs. 33)	0.84 (0.49–1.45)	0.53	0.68 (0.37–1.23)	0.20
PS 2–4 vs. 0–1 (n = 8 vs. 50)	1.29 (0.60–2.76)	0.51	0.97 (0.43–2.23)	0.95
Smoking history yes vs. no (n = 29 vs 29)	0.61 (0.36–1.06)	0.078	0.53 (0.21–1.32)	0.18
Histology sq vs. ad (n = 4 vs 54)	0.67 (0.27–1.70)	0.40	1.32 (0.46–3.83)	0.60
EGFR mutation uncommon vs. common (n = 7 vs 51)	0.57 (0.23–1.45)	0.24	0.75 (0.27–2.08)	0.58
PFS to prior EGFR TKIs > 10 vs. ≤ 10 months (n = 27 vs. 30)	2.36 (1.30–4.29)	0.005	2.87 (1.39–6.00)	0.005

PFS progression-free survival, ICI immune checkpoint inhibitor, HR hazard ratio, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor, PS performance status, advanced incurable stage III/IV, rec postoperative recurrence, sq squamous carcinoma, common EGFR exon 19 deletion and exon 21 L858R, uncommon EGFR mutations other than common ones